Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Since APOE varepsilon4 allele is also a major risk factor for the development of Alzheimer's disease (AD) and the genetic polymorphism of NPY has not previously been studied in dementing disorders, we have examined whether a novel polymorphism in a signal peptide of NPY gene is associated with AD alone or in combination with APOE varepsilon4.
|
10841982 |
2000 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
CTD_human |
During the last two decades, NPY body fluid concentrations and NPY/PYY brain receptor numbers have been demonstrated to be altered during the course of Alzheimer's disease.
|
11709213 |
2001 |
Alzheimer's Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our data support the observation, that NPY polymorphisms might influence cholesterol metabolism, but might not act as major risk factor in AD.
|
15959845 |
2006 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease.
|
19176820 |
2009 |
Alzheimer's Disease
|
0.600 |
Therapeutic
|
disease |
RGD |
We suggest that NPY, perhaps acting via NPY Y1 receptors, might interact with the endogenous cholinergic system and play a role in improving the learning and memory processes in the rats with AD-like condition.
|
22266216 |
2012 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Finally, we recapitulate our recent in-vitro evidence for the involvement of neurotrophin nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in the neuroprotective effect elicited by NPY in AD neuron-like models (neuroblastoma cells or primary cultures exposed to toxic concentrations of Aβ's pathogenic fragment 25-35), and propose a putative mechanism based on NPY-induced inhibition of voltage-dependent Ca(2+) influx in pre- and post-synaptic neurons.
|
25026432 |
2014 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overall, increased delivery of NPY to the CNS for AD might be an effective therapy especially if combined with an anti-Aβ therapeutic.
|
26620558 |
2016 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Numbers of neuropeptide Y (NPY) and parvalbumin (PV) immunoreactive (IR) cells were decreased in the hippocampus of 1 month-old TgCRND8 mouse AD model in a sub-regionally specific manner.
|
28154533 |
2016 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recently, it has been shown that NPY protects cells against neurotoxic damage from β-amyloid peptides (Aβ) in Alzheimer's disease (AD).
|
28737807 |
2017 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Copper Binding Induces Nitration of NPY under Nitrative Stress: Complicating the Role of NPY in Alzheimer's Disease.
|
30079723 |
2018 |
Alzheimer's Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Somatostatin (SOM) and Neuropeptide Y (NPY) are two neuropeptides which are expressed in GABAergic interneurons with different fates in AD the former only being markedly affected.
|
30327597 |
2018 |
Alzheimer's Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Numerous studies have indicated that the neuropeptides including ghrelin, neurotensin, pituitary adenylate cyclase-activating polypeptide (PACAP), neuropeptide Y, substance P and orexin are closely related to the pathophysiology of Alzheimer's disease.
|
30687008 |
2018 |